Periodontitis stages III-IV Oral Health
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Systematically healthy patients with the clinical diagnosis of periodontitis stage III and IV, grades B and C, according to the Classification of Periodontal and Peri-implant Diseases and Conditions 2018.
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 12/04/2024: 1. Patients who underwent antibiotic, anticoagulant or immunosuppressive therapy during the preceding 6 months 2. Patients who used oral antiseptics or received any periodontal therapy 3. Pregnant or lactating women 4. Patients in need of antibiotic prophylaxis during the preceding six months 5. Hypersensitivity against PVP-iodine and NaOCl 6. Thyroid dysfunction 7. Patients with allergies to the recommended medications 8. Systemic disorders 9. Smokers ( = 10 cigarettes per day) _____ Previous exclusion criteria: 1. Patients who underwent antibiotic, anticoagulant or immunosuppressive therapy during the preceding 6 months 2. Patients who used oral antiseptics or received any periodontal therapy 3. Pregnant or lactating women 4. Patients in need of antibiotic prophylaxis during the preceding six months 5. Hypersensitivity against PVP-iodine and NaOCl 6. Thyroid dysfunction 7. Patients with allergies to the recommended medications 8. Systemic disorders 9. Non-smokers and smokers (= 10 and = 10 cigarettes per day) were included, and a separate analysis was carried out for each category.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pocket Depth (PD) reduction. PDs were measured at six sites/tooth using a PCP-UNC calibrated probe (Hu-Friedy, Chicago, IL, USA), at baseline and after 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Full-mouth plaque scores (FMPS) were recorded using six sites per tooth. The presence of plaque was determined using disclosure solution (Dentorama Blue Disclosing Pellets Pro-155, Svenska Dentorama AB, Solna/Stockholm, Sweden), in a dichotomic way, with regard to the percentage of sites with plaque. 2. Bleeding on probing (BOP) was assessed dichotomously in 6 sites per tooth, using a periodontal probe (Force-Control Periodontal Probe WHO DB765R, Aesculap, Tuttlingen, Germany). 3. Recession (REC) were recorded to the nearest millimeter at six sites per tooth. 4. The clinical attachment level (CAL) was calculated using the PD and REC values. Measurements were rounded up to the next whole millimeter value. At the proximal surfaces, the evaluation was done in the proximity of the dental contact point, with moderate pressure. For all clinical measurements the probing force was 0.2N (20 g) using the same standardized periodontal probe. 5. Mobility was recorded in degrees, according to the Miller classification system (1985) (40). The periodontal parameters were recorded in the periodontal chart (http://www.periodontalchart-online.com/uk/), saved in .pdf format, printed and included into each patient’s observation file. Other secondary outcomes: 6. Microbiological data: In the same appointment, bacterial samples were taken as described below: to detect the 5 major keystone bacteria, Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingi-valis (Pg), Prevotella intermedia (Pi), Tanererella forsythia (Tf), and Treponema denticola (Td), a molecular genetic analysis was performed, using the commercial kit micro-IDent plus (Hain Lifescience GmbH). During the initial evaluation, samples of subgingival plaque were collected from the deepest periodontal pockets in each quadrant and used to identify the existing bacterial strains prior to treatment. This protocol was repeated at the three- month re-evaluation to assess post treatment bacterial suppression. Samples wer | — |
Countries
Romania